ERBB2 and neoplasm: The ESMO living guidelines, last updated in 2024, similarly recommends HER2 testing in all advanced/metastatic cases, recognizes the heterogeneous HER2 expression patterns in EGA tumours, and supports integrating NGS where targeted therapies are available.